Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patient With Advanced Cancer
Complete Title: A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer
Trial Phase: I
Investigator: Shailender Bhatia, MD
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with AGEN1181, and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.
Keywords:
- Neoplasms, Advanced Malignant
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Shailender Bhatia, MD
RG1122190
NCT04121676
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer
Neoplasms, Advanced Malignant